FDA 483 - Sanofi-Aventis Deutschland GmbH - January 16, 2025

**FDA 483 Summary:**

**Company Name:** [Company Name]

**Inspection Dates:** [Inspection Dates]

**Main Violations/Issues:**

1. **Microbiological Contamination Prevention:** The company lacks established and followed procedures to prevent microbiological contamination in sterile products. Critical surface environmental monitoring post-aseptic filling operations is deficient, with no microbiological surface sampling performed on product contact parts.

2. **Aseptic Processing Technique:** Inadequate aseptic processing techniques were observed, including the use of non-sterile gloves during setup and filling operations, which compromised sterility. Additionally, validation and revalidation processes for filling lines do not ensure complete sterility, as biological indicator placements are ineffective.

3. **Manufacturing Area Control:** The DS manufacturing area lacks adequate environmental controls, such as pressure and humidity systems, which are essential for maintaining product quality.

4. **Product Quality Assurance:** The current manufacturing processes do not assure product quality, as they are less stringent than previous generations.

5. **Cleaning Procedures:** There is insufficient assurance that cleaning procedures for product-contact process equipment are effective in preventing product carryover and cross-contamination. Swab sampling is not performed during cleaning validation for multi-product use or dedicated equipment.

**Regulatory Framework:** The observations are based on FDA regulations concerning sterile product manufacturing and quality assurance.

**Required Actions:** - Establish and implement robust procedures for microbiological contamination prevention. - Improve aseptic processing techniques and ensure proper validation of sterility processes. - Enhance environmental controls in manufacturing areas to ensure product quality. - Strengthen cleaning validation procedures, including swab sampling, to prevent cross-contamination.

The company is advised to address these issues promptly to ensure compliance with FDA regulations and maintain product integrity.